Skip to main content
39°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
33.90
-1.63 (-4.59%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna, Inc. - Common Stock
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
99
100
Next >
2 Big Stocks Making Big Moves Thursday
December 14, 2023
One is rising while the other's on the decline. Here's why.
Via
The Motley Fool
Why Is Moderna (MRNA) Stock Up 11% Today?
December 14, 2023
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial.
Via
InvestorPlace
Moderna Stock Is Soaring Today - Here's Why
December 14, 2023
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized...
Via
Benzinga
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
December 14, 2023
Via
ACCESSWIRE
What's Going On With Moderna (MRNA) Stock?
December 13, 2023
Moderna Inc (NASDAQ: MRNA) shares are trading lower by 4.5% to $74.50 during Wednesday's session.
Via
Benzinga
Moderna's Options Frenzy: What You Need to Know
December 08, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
December 05, 2023
Via
Benzinga
Peering Into Moderna's Recent Short Interest
December 04, 2023
Via
Benzinga
Analyst Expectations for Moderna's Future
November 29, 2023
Via
Benzinga
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
December 13, 2023
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday
December 13, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sharply during Wednesday’s session after the company...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
December 13, 2023
Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target.
Via
Investor's Business Daily
3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year
December 13, 2023
These players could lift your portfolio when they rebound and over the long term.
Via
The Motley Fool
$100 Invested In Moderna 5 Years Ago Would Be Worth This Much Today
November 24, 2023
Via
Benzinga
What's Going On With Moderna Stock Today?
December 12, 2023
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and
Via
Benzinga
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
December 12, 2023
Via
ACCESSWIRE
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
These 2 Stocks Are All-Stars in the Making
December 11, 2023
These exciting players look cheap today considering their future prospects.
Via
The Motley Fool
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
December 10, 2023
The big biotech's shares have been on the rise this year.
Via
The Motley Fool
7 F-Rated Stocks to Sell in December
December 08, 2023
If you’re holding F-rated stocks to sell, it may be too late to salvage 2023, but you can still get back on track toward achieving your goals.
Via
InvestorPlace
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
December 07, 2023
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
December 07, 2023
Via
ACCESSWIRE
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
December 06, 2023
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Dirt Cheap Stocks You'll Regret Not Buying Before the New Year
December 04, 2023
Load up on these stocks while the price is right, and hold them for the long term.
Via
The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
December 04, 2023
Vertex shares have soared 400% over the past decade.
Via
The Motley Fool
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
December 01, 2023
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepresented the efficacy of its widely-
Via
Benzinga
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
November 30, 2023
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19
Via
Talk Markets
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Upwork underscores the strength of the AI gig economy
November 28, 2023
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Feeling Lucky? 5 ‘Jackpot’ Stocks to Buy for 2024.
November 27, 2023
When investors land on a "jackpot" stock, gains can offset even the steepest losses. Here are the top stocks to buy if you're feeling lucky.
Via
InvestorPlace
Black Friday On Wall Street: 10 S&P 500 Stocks Trading At 40%+ Discount From Analysts' Expectations
November 24, 2023
Several S&P 500 stocks are trading at discounts of over 40% compared to analysts' price targets, offering potential upside, but caution is needed.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.